$KIDS
ORTHOPEDIATRICS CORP

2018 Q3 Form 10-Q Financial Statement

#000142545018000100 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $15.82M $15.08M $11.80M
YoY Change 27.84% 27.75% 22.0%
Cost Of Revenue $3.843M $3.807M $3.090M
YoY Change -59.51% 23.2% -54.73%
Gross Profit $11.98M $11.27M $8.712M
YoY Change 26.19% 29.36% 205.9%
Gross Profit Margin 75.71% 74.75% 73.82%
Selling, General & Admin $12.03M $12.28M $8.721M
YoY Change 31.88% 40.75% 22.83%
% of Gross Profit 100.42% 108.92% 100.1%
Research & Development $1.122M $1.115M $668.0K
YoY Change -0.44% 66.92% 13.22%
% of Gross Profit 9.37% 9.89% 7.67%
Depreciation & Amortization $780.0K $720.0K $590.0K
YoY Change 18.18% 22.03% 31.11%
% of Gross Profit 6.51% 6.39% 6.77%
Operating Expenses $13.15M $13.39M $9.389M
YoY Change 28.32% 42.61% 22.09%
Operating Profit -$1.172M -$2.120M -$677.0K
YoY Change 55.44% 213.15% -21.73%
Interest Expense -$610.0K -$560.0K -$650.0K
YoY Change -180.16% -13.85% 91.18%
% of Operating Profit
Other Income/Expense, Net -$693.0K -$572.0K $589.0K
YoY Change -11.27% -197.11% -35.98%
Pretax Income -$1.870M -$2.690M -$1.270M
YoY Change 21.43% 111.81% 337.93%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.865M -$2.692M -$1.266M
YoY Change 21.42% 112.64% 339.58%
Net Earnings / Revenue -11.79% -17.86% -10.73%
Basic Earnings Per Share
Diluted Earnings Per Share -$148.2K -$214.3K -$105.5K
COMMON SHARES
Basic Shares Outstanding 12.79M shares 12.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.50M $26.50M $2.300M
YoY Change 1013.64% 1052.17%
Cash & Equivalents $24.46M $26.51M $2.306M
Short-Term Investments
Other Short-Term Assets $1.000M $1.100M $1.000M
YoY Change -47.37% 10.0%
Inventory $26.90M $25.40M $19.00M
Prepaid Expenses
Receivables $9.456M $9.755M $6.500M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $61.84M $62.74M $28.80M
YoY Change 114.06% 117.83%
LONG-TERM ASSETS
Property, Plant & Equipment $12.77M $12.77M $8.200M
YoY Change 31.03% 55.73%
Goodwill
YoY Change
Intangibles $2.260M $2.340M
YoY Change -7.49%
Long-Term Investments
YoY Change
Other Assets $1.600M
YoY Change
Total Long-Term Assets $15.03M $15.11M $11.20M
YoY Change 23.31% 34.91%
TOTAL ASSETS
Total Short-Term Assets $61.84M $62.74M $28.80M
Total Long-Term Assets $15.03M $15.11M $11.20M
Total Assets $76.88M $77.85M $40.00M
YoY Change 87.13% 94.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.903M $5.455M $6.100M
YoY Change 15.7% -10.57%
Accrued Expenses $3.300M $3.200M $2.400M
YoY Change 43.48% 33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $117.0K $115.0K $100.0K
YoY Change 5.41% 15.0%
Total Short-Term Liabilities $10.92M $10.49M $10.40M
YoY Change 4.8% 0.87%
LONG-TERM LIABILITIES
Long-Term Debt $25.28M $25.30M $25.40M
YoY Change -8.08% -0.4%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $25.28M $25.30M $25.40M
YoY Change -8.08% -0.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.92M $10.49M $10.40M
Total Long-Term Liabilities $25.28M $25.30M $25.40M
Total Liabilities $36.19M $35.79M $35.80M
YoY Change -4.51% -0.03%
SHAREHOLDERS EQUITY
Retained Earnings -$112.6M -$110.8M
YoY Change 36.98%
Common Stock $2.000K $2.000K
YoY Change 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.69M $42.06M $4.200M
YoY Change
Total Liabilities & Shareholders Equity $76.88M $77.85M $40.00M
YoY Change 87.13% 94.61%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$1.865M -$2.692M -$1.266M
YoY Change 21.42% 112.64% 339.58%
Depreciation, Depletion And Amortization $780.0K $720.0K $590.0K
YoY Change 18.18% 22.03% 31.11%
Cash From Operating Activities -$1.190M -$6.640M -$4.220M
YoY Change -450.0% 57.35% 520.59%
INVESTING ACTIVITIES
Capital Expenditures -$1.160M -$1.420M -$1.510M
YoY Change -46.05% -5.96% 42.45%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$1.160M -$1.420M -$1.510M
YoY Change -46.05% -5.96% 42.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 300.0K -30.00K 5.530M
YoY Change -83.43% -100.54% 259.09%
NET CHANGE
Cash From Operating Activities -1.190M -6.640M -4.220M
Cash From Investing Activities -1.160M -1.420M -1.510M
Cash From Financing Activities 300.0K -30.00K 5.530M
Net Change In Cash -2.050M -8.090M -200.0K
YoY Change -704374636543999900.0% 3945.0% 0.0%
FREE CASH FLOW
Cash From Operating Activities -$1.190M -$6.640M -$4.220M
Capital Expenditures -$1.160M -$1.420M -$1.510M
Free Cash Flow -$30.00K -$5.220M -$2.710M
YoY Change -101.2% 92.62% -813.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
ORTHOPEDIATRICS CORP
dei Entity Central Index Key
EntityCentralIndexKey
0001425450
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12790289 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
131000 USD
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
143000 USD
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00025
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00025
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12789039 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12621781 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12789039 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12621781 shares
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2017Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2017Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2692000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1266000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7692000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2551000 USD
CY2018Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2017Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1454000 USD
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2880000 USD
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2692000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2720000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7692000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5431000 USD
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
dei Document Type
DocumentType
10-Q
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26506000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42582000 USD
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9755000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5603000 USD
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1063000 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
831000 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
62735000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
69561000 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12770000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10391000 USD
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2080000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2089000 USD
CY2018Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
260000 USD
CY2017Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
260000 USD
CY2018Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2340000 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2349000 USD
CY2018Q2 us-gaap Assets
Assets
77845000 USD
CY2017Q4 us-gaap Assets
Assets
82301000 USD
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5455000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5495000 USD
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3237000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2905000 USD
CY2018Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
115000 USD
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
113000 USD
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1683000 USD
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
954000 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10490000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9467000 USD
CY2018Q2 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
21360000 USD
CY2017Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
21418000 USD
CY2018Q2 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
3938000 USD
CY2017Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
3921000 USD
CY2018Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25298000 USD
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25339000 USD
CY2018Q2 us-gaap Liabilities
Liabilities
35788000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
34806000 USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153055000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
150424000 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110758000 USD
CY2017Q2 us-gaap Revenues
Revenues
11802000 USD
us-gaap Revenues
Revenues
27171000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103066000 USD
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-242000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
135000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
42057000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
47495000 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77845000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82301000 USD
CY2018Q2 us-gaap Revenues
Revenues
15077000 USD
us-gaap Revenues
Revenues
21564000 USD
CY2018Q2 us-gaap Cost Of Revenue
CostOfRevenue
3807000 USD
CY2017Q2 us-gaap Cost Of Revenue
CostOfRevenue
3090000 USD
us-gaap Cost Of Revenue
CostOfRevenue
6982000 USD
us-gaap Cost Of Revenue
CostOfRevenue
5437000 USD
CY2018Q2 us-gaap Gross Profit
GrossProfit
11270000 USD
CY2017Q2 us-gaap Gross Profit
GrossProfit
8712000 USD
us-gaap Gross Profit
GrossProfit
20189000 USD
us-gaap Gross Profit
GrossProfit
16127000 USD
CY2018Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6776000 USD
CY2017Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5299000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12855000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9491000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5499000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3422000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11516000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6795000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1115000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
668000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2333000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
58000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1355000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
13390000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
9389000 USD
us-gaap Operating Expenses
OperatingExpenses
26704000 USD
us-gaap Operating Expenses
OperatingExpenses
17641000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2120000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-677000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6515000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1514000 USD
CY2018Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-562000 USD
CY2017Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-650000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1114000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1095000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
61000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
572000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
589000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1177000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1037000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2692000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1266000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7692000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2551000 USD
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2692000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2720000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7692000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5431000 USD
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12549226 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1746787 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12312814 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1745390 shares
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.11
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2692000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1266000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7692000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2551000 USD
CY2018Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-459000 USD
CY2017Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
72000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-377000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
72000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-459000 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
72000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-377000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
72000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3151000 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1194000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8069000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2479000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
47495000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7692000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-377000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
2631000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
42057000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7692000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2551000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1400000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1092000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2631000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
727000 USD
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
4152000 USD
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
2428000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
232000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
727000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-40000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2569000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1061000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
531000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
377000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11673000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4234000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
180000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
300000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4167000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2844000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4347000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3144000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
8055000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-56000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8003000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
56000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
52000 USD
us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
0 USD
us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
72000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-16076000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
697000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42582000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1609000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26506000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2306000 USD
us-gaap Interest Paid
InterestPaid
1114000 USD
us-gaap Interest Paid
InterestPaid
1095000 USD
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
0 USD
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2880000 USD
kids Transfer Of Property And Equipment To Inventory
TransferOfPropertyAndEquipmentToInventory
594000 USD
kids Transfer Of Property And Equipment To Inventory
TransferOfPropertyAndEquipmentToInventory
770000 USD
us-gaap Nature Of Operations
NatureOfOperations
BUSINESS<div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;vertical-align:bottom;">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:bottom;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;vertical-align:bottom;">, PediPlates</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:bottom;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;vertical-align:bottom;">, Cannulated Screws, PediFlex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:4.22pt;line-height:120%;vertical-align:bottom;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:bottom;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;vertical-align:bottom;">nail, PediNail</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:4.22pt;line-height:120%;vertical-align:bottom;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;vertical-align:bottom;">, PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:bottom;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;vertical-align:bottom;"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, Bandloc, Pediguard and Pediatric Nailing Platform | Femur, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;vertical-align:bottom;">In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Operations began in the United Kingdom on April 3, 2017, in Australia on May 1, 2017 and in New Zealand on July 1, 2017. </span></div><div style="line-height:120%;"><span><br/></span></div><div style="line-height:120%;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;vertical-align:bottom;">On October 12, 2017, we completed an initial public offering ("IPO") of our common stock, in which we issued and sold 4,600,000 shares of common stock at a public offering price of $13.00 per share for aggregate gross proceeds of $59,800. We received approximately $46,900 in net proceeds after deducting $4,200 of underwriting discounts and commissions, paying approximately $2,700 of offering costs and paying approximately $6,000 of Series B dividends. </span></div>Our largest investor is Squadron Capital LLC (“Squadron”), a family office firm headquartered near Hartford, Connecticut.
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110758000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103066000 USD
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.
CY2018Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2018Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1115000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
668000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2333000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1355000 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q2 us-gaap Long Term Debt
LongTermDebt
25413000 USD
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
25452000 USD
CY2018Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
115000 USD
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
113000 USD
CY2018Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25298000 USD
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25339000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
70335000 USD
CY2017Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
335000 USD
CY2018Q2 kids Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation
OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation
16200000 USD
CY2018Q2 kids Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit
OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit
1062000 USD
CY2018Q2 kids Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase
OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease
2302000 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
176959 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.42
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
41594 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
27.61
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
135365 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
547670 shares
kids Classof Warrantor Right Term
ClassofWarrantorRightTerm
P10Y
CY2018Q2 kids Classof Warrantor Right Exercised
ClassofWarrantorRightExercised
0 shares
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2692000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1266000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7692000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2551000 USD
CY2018Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2017Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1454000 USD
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2880000 USD
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2692000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2720000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7692000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5431000 USD
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12549226 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1746787 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12312814 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1745390 shares
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.11
CY2018Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
347059 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4671716 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2018Q2 us-gaap Revenues
Revenues
15077000 USD
CY2017Q2 us-gaap Revenues
Revenues
11802000 USD
us-gaap Revenues
Revenues
27171000 USD
us-gaap Revenues
Revenues
21564000 USD
CY2018Q2 us-gaap Revenues
Revenues
15077000 USD
CY2017Q2 us-gaap Revenues
Revenues
11802000 USD
us-gaap Revenues
Revenues
27171000 USD
us-gaap Revenues
Revenues
21564000 USD
CY2018Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
kids Researchand Development Arrangement Contractto Performfor Others Minimum Annual Royalty Payment
ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment
500000 USD

Files In Submission

Name View Source Status
0001425450-18-000100-index-headers.html Edgar Link pending
0001425450-18-000100-index.html Edgar Link pending
0001425450-18-000100.txt Edgar Link pending
0001425450-18-000100-xbrl.zip Edgar Link pending
exhbit322-cfocertifica.htm Edgar Link pending
exhibit311-ceocertific.htm Edgar Link pending
exhibit312-cfocertific.htm Edgar Link pending
exhibit321-ceocertific.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kids-20180630.htm Edgar Link pending
kids-20180630.xsd Edgar Link pending
kids-20180630_cal.xml Edgar Link unprocessable
kids-20180630_def.xml Edgar Link unprocessable
kids-20180630_htm.xml Edgar Link completed
kids-20180630_lab.xml Edgar Link unprocessable
kids-20180630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending